Free Trial

Travere Therapeutics (TVTX) Stock Forecast & Price Target

$9.78
+0.13 (+1.35%)
(As of 07/23/2024 ET)

Travere Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 12 Wall Street analysts who have issued ratings for Travere Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 5 have given a hold rating, and 7 have given a buy rating for TVTX.

Consensus Price Target

$14.64
49.66% Upside
High Forecast$27.00
Average Forecast$14.64
Low Forecast$9.00

According to the 12 analysts' twelve-month price targets for Travere Therapeutics, the average price target is $14.64. The highest price target for TVTX is $27.00, while the lowest price target for TVTX is $9.00. The average price target represents a forecasted upside of 49.66% from the current price of $9.78.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$14.64$15.58$18.00$30.00
Forecasted Upside49.66% Upside83.94% Upside86.29% Upside53.76% Upside
Get Travere Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

TVTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Travere Therapeutics Stock vs. The Competition

TypeTravere TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.58
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside48.14% Upside3,096.68% Upside9.52% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/7/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$19.00+175.36%
5/7/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$15.00 ➝ $18.00+140.64%
4/17/2024Wedbush
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$13.00+116.31%
3/27/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral
2/16/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$8.00 ➝ $9.00+8.43%
1/18/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$10.00 ➝ $11.00+23.18%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$8.00 ➝ $10.00+17.10%
12/5/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$7.00 ➝ $10.00+58.98%
9/22/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$30.00 ➝ $14.00+89.19%
9/22/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$41.00 ➝ $27.00+253.40%
9/22/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$31.00 ➝ $12.00+57.07%
9/21/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
7/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$26.00+66.35%
5/22/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$30.00+82.37%
5/5/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral
10/20/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$45.00 ➝ $38.00+67.84%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:37 PM ET.

TVTX Forecast - Frequently Asked Questions

What is Travere Therapeutics' forecast for 2024?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Travere Therapeutics is $14.64, with a high forecast of $27.00 and a low forecast of $9.00.

Should I buy or sell Travere Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares.

Does Travere Therapeutics's stock price have much upside?

According to analysts, Travere Therapeutics's stock has a predicted upside of 87.88% based on their 12-month stock forecasts.

What analysts cover Travere Therapeutics?

Travere Therapeutics has been rated by research analysts at Canaccord Genuity Group, and HC Wainwright in the past 90 days.

Do Wall Street analysts like Travere Therapeutics more than its competitors?

Analysts like Travere Therapeutics less than other "medical" companies. The consensus rating score for Travere Therapeutics is 2.58 while the average consensus rating score for "medical" companies is 2.72. Learn more on how TVTX compares to other companies.


This page (NASDAQ:TVTX) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners